AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
(From Fair Disclosure Wire)
MAGED SHENOUDA, BIOTECHNOLOGY ANALYST, J.P. MORGAN: Good morning, and welcome to the J.P. Morgan Healthcare Conference. I'm Maged Shenouda, and I'm one of the biotechnology analysts at J.P. Morgan. It is my pleasure today to introduce Celgene. Celgene is a high-profile MidCap biotechnology company focused in the areas of oncology and inflammatory disorders. With its lead product, THALOMID, Celgene has a significant commercial presence, with over $200 million in sales for 2003. Additionally, Celgene is developing REVIMID, which is currently in registration trials for MDS, multiple myeloma, and metastatic melanoma. With us today, ...